Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

[1]  A. Tinker,et al.  Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer , 2020, JAMA oncology.

[2]  A. Jazaeri,et al.  Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). , 2020, Gynecologic oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  Rowan E Miller,et al.  Targeted therapies in gynaecological cancers , 2020, Histopathology.

[5]  Jacques Ferlay,et al.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis , 2019, The Lancet. Global health.

[6]  J. Machiels,et al.  Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Baba,et al.  Immunotherapy for Uterine Cervical Cancer , 2019, Healthcare.

[8]  A. Italiano,et al.  Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Li Wu,et al.  PD-1/PD-L1 Inhibitors in Cervical Cancer , 2019, Front. Pharmacol..

[10]  Ling-Long Tang,et al.  Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis , 2018, British Medical Journal.

[11]  C. Drescher,et al.  Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer. , 2018, Annals of Oncology.

[12]  H. Youssoufian,et al.  Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation. , 2018 .

[13]  H. Rugo,et al.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Opal L. Reddy,et al.  Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas , 2017, Diagnostic Pathology.

[15]  N. Pavlidis,et al.  Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. , 2016, Critical reviews in oncology/hematology.

[16]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[17]  M. Postow,et al.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.

[18]  Donnell,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Jordanova,et al.  Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix , 2016, Modern Pathology.

[20]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[21]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[22]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Monk,et al.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Sherman,et al.  Mortality trends for cervical squamous and adenocarcinoma in the United States , 2005, Cancer.

[25]  D. Cella,et al.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Thigpen.  Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study , 2010 .

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.